MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, recently highlighted a presentation of healthcare cost and bleeding cost data featured at the Virtual ISPOR 2021 Conference, which was held from May 17-20, 2021.
The poster presentation summarized an analysis of the IBM® MarketScan® Commercial and Medicare Supplemental claims databases and focused on patients newly initiating a P2Y12 inhibitor, factor Xa inhibitor or dabigatran between 2014 and 2018. All patients were required to present ≥1 year of continuous insurance coverage prior to initiating their therapy, and outcomes were measured while patients remained on therapy. Healthcare resource utilization measures focused on total healthcare costs, which were paid amounts from all medical and pharmacy claims, and bleed-related healthcare costs, which were paid amounts from all emergency room (ER) and inpatient (IP) hospital claims that included a diagnosis code for a bleed. Bleeding events included internal bleeds (gastrointestinal, intracranial, and other internal bleeding), external bleeds (trauma-related bleeds/amputations), and bleeding events related to medical procedures.
Results of the analyses demonstrated that, in the year prior to initiating therapy, total healthcare costs were higher among P2Y12 inhibitor patients compared to factor Xa and dabigatran patients. While on therapy, P2Y12 inhibitor patients in the commercial insurance group incurred similar total healthcare costs to factor Xa and dabigatran patients, while Medicare patients on P2Y12 inhibitor therapy incurred higher total healthcare costs than factor Xa and dabigatran patients.
The examination of costs associated with the management of bleeding events in the year prior to initiating therapy revealed that P2Y12 inhibitor patients incurred greater costs than both factor Xa patients and dabigatran patients. Costs to manage bleeding events while patients were taking their antithrombotic medication were similar across classes for both commercially-insured and Medicare patients.
These healthcare cost analyses among patients on antithrombotic medications build on separate analyses from a larger overall study that were recently presented at The American College of Cardiology’s 70th Annual Scientific Session. The previously-presented analyses demonstrated that, when compared to patients using factor Xa inhibitors or dabigatran, patients prescribed P2Y12 inhibitors have a higher burden of comorbid conditions and are potentially more likely to experience a bleeding event while taking their medication. Taken together, these conference proceedings present compelling evidence of an unmet medical and pharmacoeconomic need for an effective reversal agent for patients treated with P2Y12 inhibitors.
Jonathan P. Mow, Chief Executive Officer of PhaseBio Pharmaceuticals stated, “This analysis of real-world cost data highlights that the economic burden related to bleeding events associated with P2Y12 inhibitors is similar to commonly prescribed anticoagulants such as factor Xa inhibitors and dabigatran. With reversal agents available to help manage bleeding risks in factor Xa inhibitor and dabigatran patients, physicians, hospital systems and managed care organizations are familiar with the potential benefits of being able to quickly restore hemostasis during uncontrolled bleeding events or prophylactically avert bleeding in urgent surgery situations.” Mow continued, “The unmet need for a reversal agent for patients treated with P2Y12 inhibitors is clear, and we believe that bentracimab, if approved, has the potential to give patients and physicians an important option that could help better optimize the balance between managing thrombotic risk and bleeding risk.”
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.